The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Update: Category 2 Removals Explained Orthopedic Use of BPC 157 Sports Med Review The Pharmacology of Longevity: Peptide Edition (Part 1) FDA Reclassifies BPC 157 & TB 500 What the Research Shows #Shorts YouTube Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means